您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Denopamine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Denopamine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Denopamine图片
CAS NO:71771-90-9
包装与价格:
包装价格(元)
10mg电议
25mg电议

产品介绍
Denopamine ((R)-(-)-Denopamine) 是一种有效的,具有口服活性的的选择性 β1-肾上腺素能 (β1-adrenergic) 激动剂。Denopamine 可延长病毒性心肌炎诱发的充血性心力衰竭小鼠模型的存活时间:抑制心脏中肿瘤坏死因子-α 的产生。具有心血管效应。
Cas No.71771-90-9
别名(R)-(-)-Denopamine; TA-064
分子式C18H23NO4
分子量317.38
溶解度DMSO : 5 mg/mL (15.75 mM; ultrasonic and warming and heat to 60°C)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Denopamine ((R)-(-)-Denopamine) is an orally active, selectiveβ1-adrenergicagonist. Denopamine prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-α production in the heart. Cardiovascular effects[1].

Denopamine (0.1-100 μM) suppresses LPS-induced TNF-α production in a concentration-dependent manner[1].

Cell Viability Assay[1]

Cell Line:Murine spleen cells
Concentration:0, 0.1, 1, 10, 100 μM
Incubation Time:5 hours
Result:Decreased TNF-α levels by 96.9±6.7%, 62.7±6.5%, 53.2±8.8%, and 40.3±1.5% at 0.1, 1, 10 and 100 μmol/L, respectively.

Denopamine (14 μmol/kg per day; oral administration; for 14 days) significantly improves the survival of the animals, attenuates myocardial lesions, and suppresses TNF-α production in vivo[1].
The plasma concentration of Denopamine is 13.1±1.9 nmol/L at 1 h, 4.3±0.9 nmol/L at 2 h, 1.8±0.5 nmol/L at 3 h, and <0.6 nmol/L at 5 h after its administration. A single 14 μmol/kg dose of denopamine in mice produces a peak level at 1 h[1].

Animal Model:Four-week-old inbred male DBA/2 mice[1]
Dosage:14 μmol/kg per day
Administration:Oral administration; 14 days
Result:Treatment significantly improved the survival of the animals (14 of 25 (56%) treated, vs 5 of 25 (20%) control mice).
At day 14, the survival rate of 57.1% (16 of 28 mice) in the treated group was significantly higher than the 33.3% (10 of 30 mice) survival rate in the control group.
The survival rate from day 6 to day 14 was also significantly improved in the treated group (69.6%; 16 of 23 mice) versus the control group (45.5%; 10 of 22 mice, p < 0.05).